1. Home
  2. LICN vs LITS Comparison

LICN vs LITS Comparison

Compare LICN & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lichen China Limited

LICN

Lichen China Limited

HOLD

Current Price

$3.29

Market Cap

49.0M

Sector

N/A

ML Signal

HOLD

LITS

Lite Strategy Inc.

N/A

Current Price

$1.15

Market Cap

40.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LICN
LITS
Founded
2004
2000
Country
China
United States
Employees
N/A
4
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.0M
40.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
LICN
LITS
Price
$3.29
$1.15
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.1K
391.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$0.95
52 Week High
$8.28
$3.03

Technical Indicators

Market Signals
Indicator
LICN
LITS
Relative Strength Index (RSI) 65.71 47.11
Support Level $2.61 $0.95
Resistance Level $3.33 $1.16
Average True Range (ATR) 0.14 0.08
MACD 0.02 0.02
Stochastic Oscillator 98.05 70.21

Price Performance

Historical Comparison
LICN
LITS

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: